cherbut Posted September 3, 2004 Posted September 3, 2004 I was wondering if anyone out there has heard of TELCYTA (TLK286) manufacture by Telik. My oncologist wants me to try it. Cherbut Diagnosed Sept. 2003 Stage 4 nsclc Quote
Guest matt Posted September 8, 2004 Posted September 8, 2004 Yes, I know they are doing a clinical trial at Mass General Hosp in Boston with plans to enroll 50 people, combined with carboplatin and paclitaxel I think. Tom Lynch, MD is one of the oncologists running it. Keep us posted, Matt Quote
Guest matt Posted September 8, 2004 Posted September 8, 2004 Yes, I know they are doing a clinical trial at Mass General Hosp in Boston with plans to enroll 50 people, combined with carboplatin and paclitaxel I think. Tom Lynch, MD is one of the oncologists running it. Keep us posted, Matt Quote
john Posted September 8, 2004 Posted September 8, 2004 Bill on the board was in a clinical trial. Peg is his wife and posted here. I don't think Bill is with us anymore. I think TLK286 is supposed to make the cancer more suseptible to the chemo. It uses some mechnism related to Glutathione. If you search Glutathione and cancer and whey on google you will will find hits that purport that "whey protein" may make chemo more effective. http://www.google.com/search?hl=en&ie=U ... py&spell=1 That does not mean the trial is not appropriate for you. What are the other trials in which you can participate? http://www.targetedtherapies.org/rr.html#rr3 ------------------------------------------------------------------- TLK286 Plus Docetaxel in NSCLC Thirty-seven patients with platinum-resistant NSCLC were treated with a combination of TLK286 and docetaxel. All of the patients in the study had failed or progressed on prior platinum-based chemotherapy, and 1/3 had failed treatment with EGFR inhibitors. By RECIST criteria, a 27% objective response rate was achieved with the TLK-286-containing combination, including 7 partial responses and 1 complete response. Overall disease control rate was 67%. Historically, a response rate of 5% to 9% might be expected with single-agent docetaxel as a second-line agent in this setting. Quote
john Posted September 8, 2004 Posted September 8, 2004 This is one of the only "pub med" articles I found. There isnt much real research in this area. You have to talk to the Dr about this. Make sure you double check all info. http://www.ncbi.nlm.nih.gov/entrez/quer ... ds=8669840 Quote
Hebbie Posted September 8, 2004 Posted September 8, 2004 CHERYL!!!!!!!!!!!!!! I have no info to offer you, but wanted to say HI! I have been thinking of you recently! So good to see you! Quote
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.